DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
Why Earnings Season Could Be Great for DexCom (DXCM)
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
InMode (INMD) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
5 Must-Buy Corporate Giants Set to Beat on Earnings Tomorrow
by Nalak Das
Although corporate earnings growth was negative year over year in the first three quarters of last year, fourth-quarter results have been faring better than initially anticipated.
Shopify (SHOP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Shopify (SHOP) delivered earnings and revenue surprises of 86.96% and 4.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lithia Motors (LAD) Lags Q4 Earnings Estimates
by Zacks Equity Research
Lithia Motors (LAD) delivered earnings and revenue surprises of -4.22% and 0.40%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Barrick Gold (GOLD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Barrick Gold (GOLD) delivered earnings and revenue surprises of 21.43% and 0.84%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Chimera Investment (CIM) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chimera (CIM) delivered earnings and revenue surprises of 25.49% and 20.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment
by Zacks Equity Research
The Eco-Flex Teat Dip launch is likely to expand Ecolab's (ECL) Food & Beverage product portfolio.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed at $237.09 in the latest trading session, marking a -1.52% move from the prior day.
Best Thematic ETFs for 2020: Cloud, Internet of Things & More
by Neena Mishra
Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.
ABIOMED (ABMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Flagship Impella likely to have boosted ABIOMED's (ABMD) fiscal Q3 earnings.
Edwards Lifesciences (EW) Q4 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.